<DOC>
	<DOCNO>NCT01562886</DOCNO>
	<brief_summary>This phase I pharmacokinetic study HIV positive patient stable antiretroviral therapy switch treatment enrol nevirapine rilpivirine . On day 60 study participant attend clinic blood collect follow lumbar puncture cerebrospinal fluid collect measure drug concentration . The participant restart original regime nevirapine .</brief_summary>
	<brief_title>The Rilpivirine Cerebrospinal-fluid ( CSF ) Study</brief_title>
	<detailed_description>To investigate follow parameter HIV-infected patient switch antiretroviral therapy TDF/FTC/nevirapine TDF/FTC/rilpivirine 60 day : - CSF exposure CSF : plasma ratio rilpivirine - Safety tolerability switch antiretroviral therapy TDF/FTC/nevirapine TDF/FTC/rilpivirine - Changes cerebral metabolite measure via 1-H MRS switch antiretroviral therapy TDF/FTC/rilpivirine - Seminal fluid exposure rilpivirine</detailed_description>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>HIV1 infect male subject sign informed consent willing switch therapy per study protocol previous exposure rilpivirine plasma HIV RNA &lt; 50 copies/mL screen least one occasion last 3 month currently receive stable antiretroviral regimen comprise TDF/FTC nevirapine nevirapine dose either 200 mg twice daily 400 mg daily antiretroviral drug switch least 3 month clinicallysignificant resistance document prior HIV1 genotypic resistance test subject good health upon medical history , physical exam , laboratory test BMI equal 18 32 Male subject heterosexually active must use two form barrier contraception ( e.g. , condom diaphragm ) heterosexual intercourse , screen completion study . Have local screen laboratory result ( haematology chemistry fall within normal range central laboratory 's reference range unless result determine Investigator clinical significance No contraindication lumbar puncture examination find MRI brain current alcohol abuse drug dependence positive urine drug abuse screen active opportunistic infection significant comorbidities current disallow concomitant medication ( list section 4.1.3 ) contraindication MR examination lumbar puncture examination recent head injury ( last 30 day ) chronic ongoing neurological disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rilpivirine CSF pharmacokinetics</keyword>
</DOC>